New York, NY, United States of America

Jie Su

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 7.8

ph-index = 1


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Jie Su: Innovating Targeted Therapy with BTK Degraders

Introduction:

Jie Su, a renowned inventor in the field of pharmaceutical research, hails from the vibrant city of New York, NY (US). With a keen interest in the development of novel compounds for disease treatment, Jie Su has made significant contributions to the medical community through his groundbreaking patent on substituted pyrrolopyrimidine and pyrazolopyrimidine as Bruton's tyrosine kinase (BTK) degraders. Within the confines of Accutar Biotechnology Inc., Jie Su has been able to pioneer advanced therapeutic options for conditions influenced by BTK modulation.

Latest Patents:

Jie Su's most noteworthy patent is on substituted pyrrolopyrimidine and pyrazolopyrimidine as BTK degraders. This patent (number: [insert patent number]) presents a range of compounds (Formula I) that effectively target and degrade Bruton's tyrosine kinase. These compounds have immense potential for use in preventing and treating various conditions influenced by BTK, opening up new possibilities in targeted therapy.

Career Highlights:

Jie Su's career in pharmaceutical research has been exceptional, with accomplishments that extend beyond his groundbreaking patent:

1. Innovative Drug Discovery: Jie Su has played a pivotal role in discovering novel compounds that modulate BTK activity, offering potential solutions for various diseases.

2. Advancing Targeted Therapy: His research has contributed significantly to the development of targeted therapy approaches, improving treatment outcomes and minimizing adverse effects.

Collaborations:

Jie Su has collaborated with esteemed colleagues in his research endeavors, including Yimin Qian and Wei He, who have contributed to the success of his innovations. These collaborations highlight Jie Su's ability to foster teamwork and leverage collective expertise for groundbreaking discoveries.

Conclusion:

Jie Su's patent on substituted pyrrolopyrimidine and pyrazolopyrimidine as BTK degraders exemplifies his dedication to advancing the field of pharmaceutical research. Through his work at Accutar Biotechnology Inc., Jie Su has revolutionized targeted therapy options for conditions influenced by the modulation of BTK. As an influential inventor, he continues to inspire and shape the landscape of medical advancements, offering hope for improved treatments in the future.

For more information on Jie Su and other remarkable inventors, patents, and innovations, visit our website at idiyas.com.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…